Page last updated: 2024-11-06

tretoquinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tretoquinol is a synthetic quinoline derivative that has been studied as a potential treatment for various medical conditions. It exhibits both anti-inflammatory and anti-proliferative properties. Its synthesis typically involves a multi-step process, starting with the condensation of aniline and an aldehyde. The compound has shown promising effects in preclinical studies, demonstrating its potential as a therapeutic agent for conditions like skin disorders, inflammatory bowel disease, and certain cancers. The specific mechanisms of action are still under investigation, but it is believed to work by modulating various signaling pathways and inhibiting the production of pro-inflammatory mediators. Due to its potential therapeutic benefits, tretoquinol continues to be a subject of ongoing research to further understand its efficacy and safety for human use.'

Tretoquinol: An adrenergic beta-agonist used as a bronchodilator agent in asthma therapy. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65772
CHEMBL ID174984
CHEBI ID135461
SCHEMBL ID249003
MeSH IDM0021886

Synonyms (31)

Synonym
(1s)-1-{[3,4,5-tris(methyloxy)phenyl]methyl}-1,2,3,4-tetrahydroisoquinoline-6,7-diol
30418-38-3
tretoquinol [inn]
PDSP1_000589
tretoquinol
PDSP2_000586
CHEBI:135461
(-)-tretoquinol
tretoquinol, (-)-
s-(-)-tretoquinol
(1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol
D08629
tretoquinol (inn)
CHEMBL174984
jio3275wgi ,
tretoquinolum [inn-latin]
unii-jio3275wgi
tretochinolo
tretoquinolum
1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)-6,7-isoquinolinediol
tmq, s-(-)
nsc_65772
cas_65772
bdbm82503
(-)-1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)isoquinoline-6,7-diol
6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-, (1s)-
tretoquinol [who-dd]
SCHEMBL249003
DTXSID7023695
DB13692
Q7838878

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"No serious adverse effects, including detrimental psychological consequences, were observed with continuous LHA DBS after a mean follow-up of 35 months (range 30-39 months)."( Lateral hypothalamic area deep brain stimulation for refractory obesity: a pilot study with preliminary data on safety, body weight, and energy metabolism.
Alcindor, D; Angle, C; Bailes, J; Cantella, D; Cheng, BC; de Jonge, L; Finnis, KW; Lecoultre, V; Mizes, JS; Oh, MY; Prostko, ER; Ravussin, E; Tomycz, ND; Whiting, BB; Whiting, DM; Wilent, B, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" CV-705 was well absorbed through the digestive tract."( [Vasodilator action of (+/-)-1-(3, 4, 5-trimethoxybenzyl)-6-hydroxy-1, 2, 3, 4-tetrahydroisoquinoline hydrochloride (CV-705) in anesthetized dogs (author's transl)].
Ikezawa, K; Kiyomoto, A; Nagao, T; Nakajima, H; Sato, M, 1977
)
0.26

Dosage Studied

ExcerptRelevanceReference
"3 Dose-response curves to the four drugs for tracheal relaxation were almost parallel."( Assessment of the selectivity of OPC-2009, a new beta2-adrenoceptor stimulatn, by the use of the blood-perfused trachea in situ and of the isolated blood-perfused papillary muscle of the dog.
Himori, N; Taira, N, 1977
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID89461Inhibitory activity against phospholipase C (PLC 0.05 U/mL) induced aggregation in Human Platelets1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and investigation of the beta-adrenoceptor agonist and platelet antiaggregatory properties of 1,7,8-trisubstituted 2,3,4,5-tetrahydro-1H-2-benzazepine analogues of trimetoquinol.
AID41007Beta-2 adrenergic receptor activity in guinea pig right atrium1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Selective and potent beta 2-adrenoceptor agents within the tetrahydroisoquinoline class: effect of methyl substitution at the benzylic carbon of the 1-(3,4,5-trimethoxybenzyl) group of trimetoquinol.
AID89459Inhibitory activity against endoperoxide (U-46,619 2 uM) induced aggregation in Human Platelets1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and investigation of the beta-adrenoceptor agonist and platelet antiaggregatory properties of 1,7,8-trisubstituted 2,3,4,5-tetrahydro-1H-2-benzazepine analogues of trimetoquinol.
AID41009Beta-2 adrenergic receptor activity in guinea pig tracheal smooth muscle1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Selective and potent beta 2-adrenoceptor agents within the tetrahydroisoquinoline class: effect of methyl substitution at the benzylic carbon of the 1-(3,4,5-trimethoxybenzyl) group of trimetoquinol.
AID89462Inhibitory activity against thrombin (0.03 U/mL) induced aggregation in Human Platelets1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and investigation of the beta-adrenoceptor agonist and platelet antiaggregatory properties of 1,7,8-trisubstituted 2,3,4,5-tetrahydro-1H-2-benzazepine analogues of trimetoquinol.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (138)

TimeframeStudies, This Drug (%)All Drugs %
pre-199085 (61.59)18.7374
1990's25 (18.12)18.2507
2000's14 (10.14)29.6817
2010's14 (10.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.60 (24.57)
Research Supply Index5.01 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (5.67%)5.53%
Reviews4 (2.84%)6.00%
Case Studies8 (5.67%)4.05%
Observational0 (0.00%)0.25%
Other121 (85.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]